Clene (NASDAQ:CLNN) Posts Earnings Results, Misses Estimates By $0.05 EPS

15 May 2026, 08:32 by Jessica Moore · The Cerbat Gem

Clene (NASDAQ:CLNN – Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.05), FiscalAI reports. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million.

Clene Price Performance

CLNN opened at $7.05 on Friday. The business has a 50 day simple moving average of $5.98 and a 200-day simple moving average of $6.39. The stock has a market capitalization of $83.03 million, a P/E ratio of -2.71 and a beta of 0.89. Clene has a 12 month low of $2.28 and a 12 month high of $13.50.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Clene in a report on Monday, May 4th. D. Boral Capital reiterated a “buy” rating and issued a $23.00 price objective on shares of Clene in a report on Monday, May 4th. Weiss Ratings raised Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a research report on Friday, March 13th. Finally, Roth Mkm reissued a “buy” rating on shares of Clene in a research report on Thursday. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Clene presently has an average rating of “Moderate Buy” and an average price target of $33.25.

Read Our Latest Stock Analysis on CLNN

Insider Activity at Clene

In other news, major shareholder Chidozie Ugwumba sold 73,296 shares of the firm’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $6.20, for a total value of $454,435.20. Following the completion of the sale, the insider directly owned 103,417 shares of the company’s stock, valued at $641,185.40. This trade represents a 41.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Over the last ninety days, insiders sold 327,677 shares of company stock valued at $2,043,481. 28.30% of the stock is owned by company insiders.

Hedge Funds Weigh In On Clene

Several hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in Clene by 8.0% in the 4th quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after purchasing an additional 6,090 shares in the last quarter. Jane Street Group LLC purchased a new position in Clene in the 2nd quarter valued at approximately $47,000. State Street Corp increased its stake in Clene by 138.4% in the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares in the last quarter. Scoggin Management LP increased its stake in Clene by 42.8% in the 2nd quarter. Scoggin Management LP now owns 142,750 shares of the company’s stock valued at $558,000 after purchasing an additional 42,750 shares in the last quarter. Finally, PEAK6 LLC purchased a new position in Clene in the 4th quarter valued at approximately $294,000. 23.28% of the stock is owned by hedge funds and other institutional investors.

About Clene

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.